Lacticaseibacillus rhamnosus GR-1, a.k.a. Lactobacillus rhamnosus GR-1: Past and Future Perspectives.
- 2021-08
- Trends in Microbiology 29(8)
- M. Petrova
- G. Reid
- Jessica A. ter Haar
- PubMed: 33865678
- DOI: 10.1016/j.tim.2021.03.010
Study Design
- Type
- Review
- Methods
- Comprehensive Review
Abstract
Lacticaseibacillus rhamnosus GR-1 (LGR-1) (previously classified as Lactobacillus rhamnosus GR-1) is the most researched probiotic strain for women's health. Its various urogenital health effects, including a reduction in the recurrence of bacterial vaginosis and urinary-tract infection, are well documented. The strain has also been safely used by HIV-positive subjects, a portion of whom have reported reduced diarrhea and increased CD4 counts. Unlike most probiotic strains used for urogenital health, LGR-1 has been extensively studied for its properties, including its genomic and metabolic traits and its surface properties. This review aims to highlight the totality of research performed with LGR-1, to act as a rigorous scientific benchmark for probiotic microbes, especially for application to women's health.
Keywords: Lacticaseibacillus; Lactobacillus; STIs; bacterial vaginosis; host–microbe interaction; probiotics; urinary-tract infections; vaginal microbiota.
Research Insights
The strain has also been safely used by HIV-positive subjects, a portion of whom have reported reduced diarrhea and increased CD4 counts.
- Effect
- Beneficial
- Effect size
- Small
The strain has also been safely used by HIV-positive subjects, a portion of whom have reported reduced diarrhea and increased CD4 counts.
- Effect
- Beneficial
- Effect size
- Small
Its various urogenital health effects, including a reduction in the recurrence of bacterial vaginosis and urinary-tract infection, are well documented.
- Effect
- Beneficial
- Effect size
- Moderate
Its various urogenital health effects, including a reduction in the recurrence of bacterial vaginosis and urinary-tract infection, are well documented.
- Effect
- Beneficial
- Effect size
- Moderate
The strain has also been safely used by HIV-positive subjects, a portion of whom have reported reduced diarrhea and increased CD4 counts.
- Effect
- Beneficial
- Effect size
- Small
a portion of whom have reported reduced diarrhea and increased CD4 counts.
- Effect
- Beneficial
- Effect size
- Small
Its various urogenital health effects, including a reduction in the recurrence of bacterial vaginosis and urinary-tract infection, are well documented.
- Effect
- Beneficial
- Effect size
- Moderate
Its various urogenital health effects, including a reduction in the recurrence of bacterial vaginosis and urinary-tract infection, are well documented.
- Effect
- Beneficial
- Effect size
- Moderate
The strain has also been safely used by HIV-positive subjects, a portion of whom have reported reduced diarrhea and increased CD4 counts.
- Effect
- Beneficial
- Effect size
- Small
The strain has also been safely used by HIV-positive subjects, a portion of whom have reported reduced diarrhea and increased CD4 counts.
- Effect
- Beneficial
- Effect size
- Small
Its various urogenital health effects, including a reduction in the recurrence of bacterial vaginosis and urinary-tract infection, are well documented.
- Effect
- Beneficial
- Effect size
- Moderate
Its various urogenital health effects, including a reduction in the recurrence of bacterial vaginosis and urinary-tract infection, are well documented.
- Effect
- Beneficial
- Effect size
- Moderate